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Available online 20 December 2018Background:Neonatal encephalopathy (NE) is a leading cause of global childmortality. Survivor outcomes in low-
resource settings are poorly described. We present early childhood outcomes after NE in Uganda.
Methods:We conducted a prospective cohort study of term-born infants with NE (n = 210) and a comparison
group of term non-encephalopathic (non-NE) infants (n = 409), assessing neurodevelopmental impairment
(NDI) and growth at 27–30 months. Relationships between early clinical parameters and later outcomes were
summarised using risk ratios (RR).
Findings:Mortality by 27–30 months was 40·3% after NE and 3·8% in non-NE infants. Impairment-free sur-
vival occurred in 41·6% after NE and 98·7% of non-NE infants. Amongst NE survivors, 29·3% had NDI includ-
ing 19·0% with cerebral palsy (CP), commonly bilateral spastic CP (64%); 10·3% had global developmental
delay (GDD) without CP. CP was frequently associated with childhood seizures, vision and hearing loss and
mortality. NDI was commonly associated with undernutrition (44·1% Z-score b −2) and microcephaly
(32·4% Z-score b−2). Motor function scores were reduced in NE survivors without CP/GDD compared to
non-NE infants (median difference−8·2 (95% conﬁdence interval; −13·0,−3·7)). Neonatal clinical sei-
zures (RR 4.1(2.0–8.7)), abnormalities on cranial ultrasound, (RR 7.0(3.8–16.3), nasogastric feeding at dis-
charge (RR 3·6(2·1–6·1)), and small head circumference at one year (Z-score b−2, RR 4·9(2·9–5·6))
increased the risk of NDI.
Interpretation: In this sub-Saharan African population, death and neurodevelopmental disability after NE
were common. CP was associated with sensorineural impairment, malnutrition, seizures and highmortality
by 2 years. Early clinical parameters predicted impairment outcomes.chool of Hygiene and Tro
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Neonatal encephalopathy (NE) is the third leading cause of under 5-
year mortality and contributes substantially to long-term neurological
morbidity worldwide [1]. Neonates affected by a perinatal insult typi-
cally present with NE, a descriptive term for a clinical constellation ofense (http://creativecommons.org/licenses/by/4.0/).
Research in context
Evidence before this study
We searched Pubmed, and subsequent lists of relevant arti-
cles, without date or language restrictions, with combinations of
the terms ‘neonatal encephalopathy’ (NE) ‘asphyxia neonatorum’,
‘birth asphyxia’, ‘perinatal asphyxia’, ‘hypoxic-ischaemic encepha-
lopathy’, and ‘outcomes’, ‘neurodevelopment’, ‘disability’, and ‘im-
pairment’ onMar 25, 2018. NE has been estimated to affect 1·15
million infants around the world each year, including 478,000 in
sub-Saharan Africa. A systematic review of long-term
neurodevelopmental outcomes after intrauterine and neonatal in-
sults showed one in five infants to be at risk of severe impairment
in at least one domain; however, contributing data from low and
middle-income countries (LMICs) were scarce. A pooled estimate
of neonatal case fatality rates after NE in high mortality settings
was reported as 27·7% (95%CI:18·7%–36·6%). Only two previ-
ous sub-Saharan studies (one each from Tanzania and South
Africa) have reported impairment outcomes after NE. Both
followed the NE survivors to ≤1 year, when impairment outcomes
are less clearly defined and neither included a comparison cohort.
The Tanzanian study reported impairment outcomes (defined as
abnormal tone, convulsions, developmental delay or cerebral
palsy) to only 6 months of age (n = 82). The second, from a ter-
tiary South African centre, reported a prevalence of moderate–
severe impairment of 33·3% after NE using a comprehensive
neurodevelopmental assessment at one year of age, albeit
amongst a small cohort of 36. We could find no studies reporting
on later childhood outcomes amongst survivors of NE in sub-
Saharan Africa.
Added value of this study
To our knowledge, this study is the largest cohort study to fol-
low, comprehensively assess and describe early childhood out-
comes amongst infants with NE in sub-Saharan Africa. We have
documented high mortality to 27 months amongst children with
NE, with most deaths occurring in the neonatal period. A third of
survivors were affected by neurodevelopmental impairments, in-
cluding cerebral palsy (CP) and severe global developmental dis-
ability without motor impairment. Bilateral spastic CP with
dystonia was common and strongly associated with multi-
domain impairment, visual and hearing loss, undernutrition and
childhood seizures. Mortality at two years was high amongst chil-
dren identified to have CP. NE survivors without CP or global de-
velopmental delay were still at increased risk of delayed fine and
gross motor functioning. Simple neonatal clinical parameters as-
sociated with adverse outcome included severity of NE, presence
of neonatal seizures, abnormalities on cranial ultrasound and per-
sistent early feeding difficulties. A small head circumference at
one year strongly predicted adverse outcome at two. Only four
out of ten infants with NE experienced disability-free survival at
two years of age.
Implications of all the available evidence
Children with NE in sub-Saharan African are at high risk of
death and neurodevelopmental impairment with likely substantial
impact on affected children and their families. Bilateral spastic
CP, commonly associated with multi-domain impairments, sei-
zures and malnutrition, affect many NE survivors in a region
where access to supportive services are frequently lacking. Since
studies examining the aetiology of CP often use a lower age cut-
off of 2 years, the high burden of early mortality amongst children
with severe impairmentmeans that the contribution ofNE to child-
hood disability is likely under-estimated. Simple early clinical pre-
dictors may support a targeted approach to follow-up of
particularly high-risk children. Strategies for the prevention of
NE, and early identification and intervention for those affected
by impairment are needed to improve early childhood outcomes
and quality of life for affected children and their caregivers. Cur-
rent understanding of longer-term childhood outcomes of NE in re-
source poor settings is limited, but necessary if we are to
understand the full impact of perinatal events on the life chances
of affected children.
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amongst NE survivors include cerebral palsy (CP), global developmental
delay (GDD), vision and hearing impairments and seizure disorders [3].
A systematic review of follow-up amongst high-risk newborns showed
that one in ﬁve infants were at risk of severe impairment in at least one
domain; however, few contributing data came from low and middle-
income countries (LMICs) and in particular sub-Saharan Africa [4]. A
common limitation of outcome studies amongst high-risk neonates is
following to ≤1 year of age when neurodevelopmental impairment
may be missed and diagnosis and classiﬁcation of CP not possible [2].
Worldwide, 80% of the estimated 200 million children with physical
and intellectual disability live in LMICs where implications for the
health, wellbeing and life chances of affected individuals, families and
communities are far-reaching [5,6]. Early childhood development has
been recognised as one of the pillars of the Global Strategy forWomen's,
Children's and Adolescents' Health, to ensure that children not only sur-
vive, but also thrive [7]. Childrenwith GDD and other disabilities are vul-
nerable to health inequalities [8] and the social, emotional and ﬁnancial
impact on caregivers and other family members is high [9]. A focus on
early child development is crucial to achieving the Sustainable Develop-
ment Goals, to ensure that all children have the opportunity to maxi-
mise their full developmental potential and to improve life chances for
themselves and their families [10].
The primary aim of our study was to determine the
neurodevelopmental status of survivors of NE at 27–30 months of age
in Uganda compared to a comparison cohortwithout NE and to describe
the type and severity of neurodevelopmental impairment (NDI) in NE
survivors. In addition, we aimed to describe nutritional status and iden-
tify clinical predictors for impairment outcomes after NE in this low-
resource sub-Saharan African setting.
2. Methods
2.1. Setting
Uganda is a low-income country (LIC)with a neonatal mortality rate
of 27 per 1000 live births [11]. Mulago National Referral Hospital in
Kampala receives high-risk pregnancies from the surrounding areas.
In 2012, more than 33,000 deliveries occurred on the low- (21%) and
high-risk (79%) labour wards. In labour, fetal monitoring was by inter-
mittent auscultation using a Pinard stethoscope and women were not
routinely examined at the start of the second stage. Ventouse/forceps
assisted deliveries were not routinely offered. A ﬁfth of deliveries
were by caesarean section (few are electively planned). Intravenous
ﬂuids, antibiotics and syntocinon were available. Midwife-led neonatal
resuscitation included oxygen and bag-mask ventilation. Care on the
70-bed Special Care Baby Unit included simple continuous positive air-
way pressure ventilation, intravenous ﬂuids including glucose (but not
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but notmechanical ventilation, therapeutic hypothermia, cerebral func-
tion monitoring or brain imaging.
The study protocol was approved by the Uganda Virus Research In-
stitute Research Ethics Committee, Mulago Ethics Committee, London
School of Hygiene and Tropical Medicine, University College London
and the Uganda National Council of Science and Technology.
2.1.1. Study Design and participants
This study was a hospital-based prospective cohort study of
neurodevelopmental outcomes at 27–30 months amongst term-born
infants affected by NE and a contemporaneously recruited unmatched
comparison group of term-born infants without NE (non-NE group).
All participants were born at ≥37 weeks gestation and originally re-
cruited to the ABAaNA case-control study [12] designed to investigate
perinatal risk factors for NE in a low-resource African setting. NE was
deﬁned as a Thompson score [13] ≥6 within 12 h of birth [12]. For the
controls, mothers and infants were systematically sampled from the la-
bour ward admission book and were eligible for recruitment if their
Thompson score was b3 (Fig. 1).
Exclusion criteria included mother living N20 km from the hospital
(up to 20 km was deemed a reasonable distance for a new mother to
travel for the 4–6 week postpartum study assessment), out-born in-
fants, and no informed written consent. Infants with congenital abnor-
malities or other pathology were not excluded but a major anomaly
was uncommon. Full study procedures and ﬁndings of the original
case-control study have been described previously [12,14,15]. Socio-
economic status was derived using principal components analysis of
household characteristics and assets and categorised into tertiles.
2.1.2. Measuring Clinical Predictors of Impairment Outcome
Encephalopathy was graded (mild, moderate or severe) from the
most severe day (days 1–5) using a modiﬁed Sarnat classiﬁcation [16].
Methods for measuring clinical predictors of outcome such as clinical
seizures, hypothermia andneonatal serious bacterial infection have pre-
viously been described [14].
Cranial ultrasound scans (cUS) were performed on encephalopathic
infants and the ﬁrst 100 comparison children on recruitment (previ-
ously reported [15]) and again between days 3 and 5, using a portable
machine (z.one ultra-Convertible Ultrasound System; Zonare Medical
Systems Inc. Mountain View, California, USA). Imageswere anonymised
and downloaded (OsiriX software, Geneva, Switzerland) and reported
(by FC and CH), blinded to clinical data. The presence of recent and
evolving injury was deﬁned as clearly demarcated focal bilateralFig. 1. Diagram showing how particiechogenicity in BGT and/or diffuse moderate, severe or dense
echogenicity in WM [15].
2.1.3. Follow-up Procedures
After discharge, families were contacted from comprehensive loca-
tor information collected at recruitment. Where a death was reported
informationwas collected on date of death and parental report of causa-
tion. Surviving children were assessed at 4–6 weeks as part of the orig-
inal study. Further fundingwas later awarded to see the children ﬁrst at
12–15 months and then again at 27–30 months of age. Informed con-
sent was taken individually at each of these visits. Transport costs
were remunerated. Families not contactable by phone were visited at
home (b5%). Informed written consent from caregivers was obtained.
This article focuses on neurodevelopmental and nutritional outcomes
at 27–30 months.
2.1.4. Neurodevelopmental Assessment at 27–30 Months
Weused theGrifﬁthsMentalDevelopmental Scales-II (GMDS) to de-
rive an overall Development Quotient (DQ) from the six subscales (A to
F) [17]. Assessors were trained study staff (MMB, FC, CT, RL, JS, KB, JM,
EDB, KN) and all certiﬁed in GMDS and blind to presence of NE, all clin-
ical history and imaging results.
All children were examined neurologically using a standardised
scorable assessment, the Hammersmith Infant Neurological Examina-
tion (HINE), that has been validated as a predictor of motor outcome
in different cohorts [18,19]. The HINE is accessible, easy to perform
and has good inter-observer reliability, even with inexperienced staff
[18]. Optimal scores in term-born infants at 18 months are 75–78. A
score of ≥67 at 9–14 months was predictive of independent walking
at 2 years in a term-born cohort following hypoxic-ischaemic encepha-
lopathy [20].
CP was diagnosed and classiﬁed according to the Surveillance of Ce-
rebral Palsy in Europe hierarchical classiﬁcation [21]; spastic bilateral,
spastic unilateral, dyskinetic, dystonic, choreo-athetotic, ataxic or non-
classiﬁable. CP severity was classiﬁed using the Gross Motor Function
Classiﬁcation System for Cerebral Palsy (GMFCS) [22]. Videos for all chil-
dren with a suboptimal HINE score were reviewed by a minimum of
two investigators (blind to NE status and other clinical data) with ex-
pertise in neurodevelopmental impairment (CT, FC and MMB) to type
and classify the NDI. There was consensus between experts on impair-
ment type and classiﬁcation for all impaired children.
Neurodevelopmental impairment (NDI) was deﬁned as a global DQ
b 70 on GMDS and/or HINE score b 67 and/or diagnosis of CP. Poor out-
come was deﬁned as a composite of death or NDI at 27–30 months.pants moved through the study.
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Visual and hearing assessments were conducted according to HINE
standardised procedures. In the HINE, intermittent or continuous devi-
ation of the eyes or abnormalmovements are noted aswell as the ability
to ﬁx and follow on a clear black/white target; a hearing response is
noted by a reaction to a stimulus (a rattle) held behind a visual range
on each side. A score of b1 (not following a visual target or not
responding to an auditory stimulus) was used to deﬁne severe visual/
hearing impairment.
2.1.6. Anthropometrics and Health
Occipito-frontal head circumference (OFC, paper tape measure),
weight, (SECA336 electronic scales, Hamburg, Germany) and height
were taken by study staff using standardised procedures [23].
Haemoglobin (Hb) was determined on a ﬁnger prick sample using
HemoCue Hb 201 (HemoCue AB, Angelholm, Sweden). Quality control
was performed weekly following manufacturer's recommendation
(HemoTrol, level 3). A structured maternal interview in Luganda
reported on caregivers concerns regarding health, growth and develop-
ment and episodes of illness including seizures and other neurological
problems, feeding difﬁculties, chest infections, and treatment for
malnutrition.
2.2. Statistical Analysis
The primary outcome for this analysiswas NDI (a composite of GMDS,
HINE and CP, as deﬁned above) at N2 years of age (27–30months) when
important outcomes, such as cerebral palsy, can be conﬁdently diagnosed
and classiﬁed. Secondary outcomes included GMDS and its subscales,
HINE, CP, vision and hearing impairment, GDD without CP, and nutri-
tional outcomes, all at 27–30 months. All-cause mortality to 30 months
and poor outcome at 30 months (NDI or death, as described above)
were also included as secondary outcomes. The primary comparisons
were done between the NE cohort and non-NE children. Secondary com-
parisonsweremade between the same groups after excluding thosewith
deﬁned NDI from both groups.
We aimed to assess outcomes in at least 110 children with NE
and 220 non-NE children, a sample size giving 80% power toFig. 2. Flow diagramdetect a difference in mean DQ of 3.75 between the two groups,
using Satterthwaite's t-test with unequal variances and assuming
SD of 12 and 10 in exposed and unexposed cohorts, respectively
[3].
Neonatal mortality was calculated as the percentage of neonatal
deaths amongst those for whom vital status was known at 28 days.
Post-neonatal mortality was calculated as the percentage of deaths
amongst participants who survived to 28 days and for whom vital
status was known at the end of 27 months of follow-up. Kaplan-
Meier graphs were plotted, with children censored at loss to
follow-up. Post-neonatal mortality was compared between NE
and non-NE groups using chi-squared and log rank tests. Socio-
demographic and baseline characteristics of participants were
compared between NE and non-NE groups, using chi-squared
tests and t-tests, as appropriate. Neurodevelopmental outcomes
were compared between NE and non-NE groups; deviation from
normality for GMDS and HINE scores meant median scores were
calculated and compared using generalised Hodges-Lehmann me-
dian differences and 95% conﬁdence intervals (CI), and the
Wilcoxon rank sum test.
The proportion of children with neurodevelopmental, vision and
hearing impairment at 27–30 months was calculated, with risk ratios
and 95% CI using the non-NE cohort as the reference group, and P-
values from chi-squared/Fisher's exact test. World Health Organisation
data [24] were used to calculate weight-for-age and height-for-age Z-
scores. OFC Z-scores were derived using the mean and SD from the
non-NE group. Proportionswith Z-scores b−2 and−3were compared
using risk ratios as above.
In secondary analyses, to assess whether outcomes after NE dif-
fered from the non-NE cohort, in the absence of deﬁned NDI, analy-
ses were repeated, comparing non-NDI encephalopathy survivors
and non-NDI comparison cohort members. Clinical characteristics
of children with NDI amongst both cohorts, including type and se-
verity, were described.
The risk of poor outcome (death or NDI) and the risk of NDI amongst
NE survivors were calculated according to severity of NE and other early
clinical ﬁndings. Early clinical predictors of poor outcomewere reported
using risk ratios.of participants.
Table 1
Baseline and clinical characteristics amongst neonatal encephalopathy (NE) survivors and
the comparison, non-NE cohort - children seen at 27–30 months.
Clinical characteristic Encephalopathy
cohort N = 116
n (%)
Comparison
cohort N = 230
n (%)
p-value⁎
Maternal Factors
Socio-economic
group (SES)
High 18 (15·7%) 49 (21·7%) 0·36
Medium 78 (67·8%) 147 (65·0%)
Low 19 (16·5%) 30 (13·3%)
Maternal age in years, mean
(SD)
23·6 (5·2) 24·9 (5·4) 0·03
Maternal education ≤
primary school
41 (35·3%) 84 (36·7%) 0·81
Maternal primaparity 65 (56·0%) 84 (36·5%) 0·001
Maternal HIV positive 5 (4·3%) 27 (11·7%) 0·02
Emergency caesarean
section
24 (20·9%) 38 (16·5%) 0·32
Infant factors
Male sex 82 (70·7%) 114 (49·6%) b0·001
Birth weight in kg, mean
(SD)
3·24 (0·44) 3·16 (0·46) 0·14
Birth occipito-frontal head
circumference in cm, mean
(SD)
35·5 (1·8) 34·9 (1·7) 0·004
Postnatal factors
Apgar score at 5 min ≤5 39 (39·0%) 0 (0%) b0·001
Need for any resuscitation 87 (95·6%) 33 (15·1%) b0·001
Clinical features
Grade of
encephalopathya
Mild 20 (17·2%) –
Moderate 74 (63·8%) –
Severe 22 (19·0%) –
Neonatal clinical seizures 56 (48·3%) 0 (0%) b0·001
Hypothermia: axillary
temperature b 36·5Cb
88 (77·2%) 52 (23·9%) b0·001
Hyperthermia: axillary
temperature N 37·5Cb
9 (7·8%) 4 (1·8%) 0·008
Haemoglobin in g/L, mean
(SD)b
169 (26) 181 (20) b0·001
Missing data for SES (1 NE, 4 comparison), maternal education (1 comparison), Apgar
scores (16 NE, 3 comparison), need for resuscitation (25 NE, 11 comparison), temperature
(12 comparison), haemoglobin (30 comparison).
a Encephalopathy graded on the most severe day (days 1–5) according to Sarnat &
Sarnat classiﬁcation [16].
b Temperature and haemoglobin measured during day 1.
⁎ p-values calculated using chi-squared tests or Fisher's exact test for categorical data
and t-tests for continuous data.
30 C.J. Tann et al. / EClinicalMedicine 6 (2018) 26–352.3. Role of the Funding Source
The study funders have no role in the study design, development or
execution, data collection, analysis or interpretation, nor in the paper
design, writing or decision to submit for publication. CJT had full access
to all study data and ﬁnal responsibility for the decision to submit for
publication.
3. Results
Between September 2011 and October 2012, 210 infants were re-
cruited to the NE cohort and 409 infants to the non-NE cohort. Charac-
teristics of participants and predictors of NE identiﬁed in the original
case-control study have been published [12].
3.1.1. Follow Up at 27–30 Months
Assessment at 27–30 months was achieved in 116 children with NE
and 230 of the non-NE cohort. Details of the follow-up of the cohorts
are given in Fig. 2. Thus, outcome data (known death or NDI outcome)
was available for 93·8% (197/210) of the original NE cohort and 58·4%
(239/409) of the original non-NE group; 71% allowing that 53 children
were deliberately excluded when the desired follow-up number was
achieved. Non-NE cohortmothers not seen at 27–30monthswere, on av-
erage, younger, poorer, and primiparous and their infants were of lower
birth weight than those that were followed (Supplementary Table).
Baseline and early clinical characteristics of the encephalopathy and
non-NE groups seen at 27–30 months are shown in Table 1. Mothers of
NE survivors were, on average, younger, more likely to be primiparous
and less likely to beHIV positive than comparisonmothers reﬂecting as-
sociations with NE reported in the original case-control study [12]. En-
cephalopathy survivors were more likely to be male, have a higher
birth OFC, a poor 5-minute Apgar score, and to need resuscitation
after birth. The majority had moderate or severe encephalopathy
(82·8%) and almost half (48.3%) had clinical neonatal seizures.
3.1.2. Neurodevelopmental Impairment Outcomes After NE vs. Term Non-
Encephalopathic Infants
Table 2 shows the neurodevelopmental and nutritional outcomes
amongst NE survivors and the non-NE group. Nearly a third of NE survi-
vors (29·3%) had NDI (compared to 1·3% of comparators); 19·0% had
CP (all with other impairments) and 10·3% had GDD without CP.
16·4% of NE survivors either needed assistive devices for walking or
were non-ambulant (GMFCS III-V). Amongst those with CP, median
DQ was 31.1 (interquartile range (IQR): 5.1–50.0) compared to 60.0
(IQR: 53.1–66.1) for those with GDDwithout CP (p= 0·0015). Median
HINE score was 41·5 (IQR: 20.1–49.1) and 76·3 (IQR: 73.3–77.8) for NE
survivors with CP versus thosewith GDDwithout CP (p b 0·001). In the
non-NE children, two developed mild CP, one GDD and one had an
isolated hearing impairment. Amongst the 197 children with NE,
disability-free survival occurred in only 41·6% (n = 82) of the original
cohort. Fig. 4 shows the distribution of DQs for impaired survivors, un-
impaired survivors and non-NE cohort. No child was categorised as
being impaired based solely on sub-optimal HINE scores (b67).
Neurodevelopmental outcomes were compared between children
without CP and GDD from both the NE and non-NE group to look for
more subtle developmental delays (Table 3, Fig. 4). Signiﬁcant differ-
ences were seen in median DQ (−2·9(95% CI:−5·1,−0·7)) and for
gross and ﬁne motor function scores (Locomotor, −8·2(95% CI:
−13·1,−3·7) and Eye & Hand,−4·5(95% CI:−8·0–0·8)). Although
the median HINE score was the same in the two groups, the range
was considerably wider for NE survivors leading to a statistically signif-
icant difference in HINE distribution. Suboptimal HINE scores (67–74)
were seen in two NE survivors (DQs 102 and 98) and two non-NE chil-
dren (DQ's 82 and 86) without CP or GDD. All were walking at two
years.Childhood seizures occurred in 5·7% of non-NE children (none on
regular medication) but were more common amongst NE survivors
(12·9%, RR 2·3) with 27% on regular medication. No signiﬁcant differ-
ences were seen between NE children without CP or GDD and non-NE
children for childhood seizures (data not shown).
3.1.3. Type of Neurodevelopmental Impairment Seen
Table 4 details the clinical characteristics of children with NDI (34 NE
survivors, 3 non-NE). Spastic bilateral CP was the commonest type of CP
(63·6%) and was frequently associated with dystonia, 10 children had
identiﬁed seizures (most with CP) and nearly half had under-nutrition.
Nine children with NDI were microcephalic (z-score b−3), two-thirds
with bilateral spastic CP and a third with GDD.
All non-NE children were ambulant and none microcephalic, but
two had CP (one mildly diplegic and one dystonic) and low DQs. An-
other child had GDD without motor impairment and one had profound
hearing loss but DQ and HINE scores within normal range. All children
with GMFCS scores 3–5 (moderate-to-severe cerebral palsy) had low
HINE scores and all those with global developmental disability but no
cerebral palsy had scores N67. The underlying aetiologies were unclear.
3.1.4. Nutrition and Other Health Outcomes in NE Survivors
NE survivors were signiﬁcantly more likely to have moderate
(RR1·9) or severe (RR7·9) under-nutrition compared to non-NE
Table 2
Developmental and nutritional outcomes between neonatal encephalopathy (NE) survivors and the comparison cohort (non-NE term infants) at two years of age.
Encephalopathy cohort
(N = 116)
Comparison cohort
(N = 230)
Median difference
or RR (95% CI)a
p-value†
Developmental and neurology outcomes
Grifﬁths Mental Development Scales
Locomotor 84·5 (68·3, 106·8) 107·4 (89·5, 122·0) -20·5 (−27·4,−13·9) b0·001
Personal social 106·2 (74·8, 116·7) 112·2 (102·1, 124·9) −11·3 (−11·5,−1·0) b0·001
Speech & hearing 85·3 (55·4, 88·2) 87·6 (83·0, 94·8) −7·4 (−12·0,−3·7) b0·001
Eye & hand 86·9 (64·8, 95·8) 99·7 (87·4, 110·1) −14·5 (−19·1,−9·0) b0·001
Performance 76·8 (64·7, 82·8) 81·5 (76·1, 85·0) −5·0 (−7·6,−2·8) b0·001
Practical reasoningb 90·4 (85·1, 99·6) 95·7 (87·5, 103·0) −3·7 (−6·8,−0·5) 0·02
Global developmental quotient (DQ) 90·4 (66·2, 97·5) 97·6 (91·1, 103·9) −9·4 (−13·2,−5·8) b0·001
Neurodevelopmental impairment (DQ b 70) 31 (26·8%) 1 (0·4%) RR 61·5 (8·5, 444·6) b0·001
Hammersmith Infant Neurological Examination (HINE)c 77·8 (range 12·0, 78·0) 78·0 (range: 58·5, 78·0) 0 (−0·5, 0) b0·001
Neurological score sub-optimal [18] (HINEb67) 21 (18·1%) 1 (0·4%) RR 40·9 (5·6, 300·4) b0·001
Vision
Visual impairment, no NDI 0 0 0·004
Visual impairment, with NDI 5 (4·3%) 0
Hearing
Hearing impairment, no NDI 0 1 (0·4%) RR 4·0 (0·4, 43·3)d 0·22
Hearing impairment, with NDI 2 (1·7%) 0
Cerebral Palsy 22 (19·0%) 2 (0·9%) RR 21·8 (5·2, 91·2) b0·001
Motor impairment: GMFCS
Mild CP (GMFCS I-II) 3 (2·6%) 2 (0·9%) RR 3·6 (0·6, 21·0)e 0·13
Severe CP (GMFCS III-V) 19 (16·4%) 0 (0%)
Global developmental delay (GDD), no CP 12 (10·3%) 1 (0·4%) RR 23·8 (3·1, 180·8) b0·001
Any neurodevelopmental impairmentf 34 (29·3%) 3 (1·3%) RR 22·5 (7·1, 71·6) b0·001
Childhood seizuresg 15 (12·9%) 13 (5·7%) RR 2·3 (1·1, 4·6) 0·02
Occipito-frontal head circumference (at 2 years)h
Z-score b−2 (b45·8 cm) 16 (13·8%) 7 (3·0%) RR 4·5 (1·9, 10·7) b0·001
Z-score b−3 (b44·3 cm) 10 (8·6%) 0 b0·001
Any neurological sequelae including CP, GDD, profound
visual or hearing loss or childhood seizures
39 (33·6%) 17 (7·4%) RR 4·8 (2·8, 8·3) b0·001
Nutritional outcomes
Moderate under-nutrition:
weight-for-age Z-score b−2
18 (15·6%) 19 (8·3%) RR 1·9 (1·0, 3·4) 0·04
Severe under-nutrition:
weight-for-age Z-score b−3
12 (10·3%) 3 (1·3%) RR 7·9 (2·3, 27·6) b0·001
Wasting: weight-for-height Z-score b−2i 8 (6·9%) 11 (4·8%) RR 1·4 (0·6, 3·5) 0·42
Stunting: height-for-age Z-score b−2i 33 (28·4%) 45 (19·7%) RR 1·4 (1·0, 2·1) 0·06
Anaemia
Haemoglobin (Hb), mean (SD) 10·5 (1·4) 10·8 (1·3) −0·3 (−0·6, 0·0) 0·03
Anaemia (Hb b11·0 g/dL) 72 (62·1%) 130 (56·5%) RR 1·1 (0·9, 1·3) 0·32
Data shown are median (IQR) for continuous data unless otherwise indicated, and n (%) for categorical data. CP=Cerebral palsy, DQ=Developmental quotient, GDD= Global develop-
mental delay, NDI=Neurodevelopmental impairment, RR = risk ratio.
a Generalised Hodges-Lehmannmedian differences for continuous data and RR for categorical data for the encephalopathy cohort using the comparison cohort as the reference group.
b Not available for 31 encephalopathic survivors for whom the global DQ was calculated as the mean of the remaining ﬁve subscales.
c Not done for 4 children in the comparison cohort.
d RR calculated for any hearing impairment versus none.
e RR calculated for GMFCS I-II (milder impairment) versus GMFCS = 0. RR could not be calculated for GMFCS III-V (severe impairment).
f Neurodevelopmental impairment: global DQ b70 and/or HINE b67 and/or diagnosis of CP.
g Deﬁned as seizures outside the neonatal period.
h Cut-offs for head circumference was determined as comparison group mean – 2 comparison group SD and mean – 3 comparison SD.
i Not available for 1 child in the comparison cohort.
† p-value fromWilcoxon rank sum test (continuous data) or chi-squared test (categorical data)/Fisher's exact test (categorical data with expected cell count b5).
Table 3
Developmental and neurology outcomes in unimpaired neonatal encephalopathy (NE) survivors and unimpaired non-NE comparison cohort at two years.
Encephalopathy cohort (n = 82) Comparison cohort (n = 227) Median difference (95% CI)a p-value†
Developmental outcomes
Locomotor 100·0 (81·4, 111·2) 107·4 (90·6, 122·1) −8·2 (−13·1,−3·7) b0·001
Personal Social 112·0 (102·2, 122·1) 112·3 (102·5, 124·9) −0·3 (−4·5, 3·8) 0·89
Speech & hearing 87·1 (83·0, 90·7) 87·7 (83·2, 95·0) −1·4 (−3·5, 0·5) 0·17
Eye & hand 93·4 (86·1, 101·5) 100·6 (87·5, 110·1) −4·5 (−8·0, 0·8) 0·02
Performance 81·1 (76·0, 84·1) 81·6 (76·4, 85·1) −0·9 (−2·4, 0·5) 0·21
Practical reasoning 91·5 (86·1, 101·0) 95·9 (88·1, 103·2) −2·3 (−5·4, 0·7) 0·13
Global developmental quotient 95·3 (89·4, 101·2) 97·7 (91·4, 104·1) −2·9 (−5·1,−0·7) 0·01
Neurology
Hammersmith Infant Neurological Examination scoreb 78·0 (range: 68·0, 78·0) 78·0 (range: 73·0, 78·0) 0 (0, 0) b0·001
'Unimpaired'=survivors without cerebral palsy or global developmental delay. Data shown are median (IQR) for continuous data and n (%) for categorical data.
a Generalised Hodges-Lehmann median differences for continuous data.
b Not done for 4 children in the comparison cohort.
† p-value fromWilcoxon rank sum test.
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Table 4
Clinical characteristics of children with neurodevelopmental impairment at two years of age amongst survivors of neonatal encephalopathy (NE) and the comparison, non-NE cohort.
No NE Sarnat
[16] stage
Age when
assessed (months)
HINE DQ Cerebral
Palsy
GMFCS Hearing/visual
impairment
Childhood
Seizures
OFC cm
(z-score)
Weight-for-age
(z score)
Walking by
2 years
Type of neurodevelopmental
impairment
Encephalopathy survivors
1 2 27·0 13 3·3 Yes 5 VI Yes 39·0 (−6·98) −3·33 No Spastic bilateral CP, dystonia,
microcephaly
2 3 27·3 45·5 17·9 Yes 3 None Yes 40·0 (−6·27) −4·14 Yes AT Spastic bilateral CP, dystonia,
microcephaly
3 2 27·0 30 8·3 Yes 5 VI Yes 40·2 (−6·11) −6·49 No Spastic bilateral CP, dystonia,
microcephaly
4 2 27·1 18·5 1·7 Yes 5 HI &VI Yes 42·3 (−4·59) −3·75 No Spastic bilateral CP, mild
dystonia, microcephaly
5 3 28·7 17·5 2·8 Yes 5 VI No 42·0 (−4·12) −3·92 No Spastic bilateral CP, no dystonia,
microcephaly
6 3 28·3 19 1·9 Yes 5 HI & VI No 43·5 (−3·80) 2·00 No Spastic bilateral CP, no dystonia,
microcephaly
7 3 29·6 24 5·7 Yes 5 None Yes 45·2 (−1·91) −4·38 No Spastic bilateral CP with dystonia
8 3 29·6 45·5 31·8 Yes 4 None No 43·8 (−2·91) −3·32 No Spastic bilateral CP with dystonia
9 2 29·5 42 38·6 Yes 3 None No 47·0 (−1·36) −2·27 Yes AT Spastic bilateral CP with dystonia
10 2 28·8 48·5 49·7 Yes 3 None Yes 50·2 (+1·71) −1·26 No Spastic bilateral CP no dystonia
11 3 27·1 33·5 31·4 Yes 4 None No 45·8 (−1·28) −1·10 No Spastic bilateral CP with dystonia
12 2 26·9 20·5 11·1 Yes 5 None Yes 49·7 (1·52) −4·39 No Spastic bilateral CP marked
dystonia,
13 2 27·0 41 33·3 Yes 3 None No 49·8 (1·58) −1·35 No Spastic bilateral CP legs more
than arms
14 3 27·4 12 2·1 Yes 5 None No 45·0 (−1·88) −3·94 No Spastic bilateral CP no dystonia
15 2 27·7 46 50·9 Yes 4 None No 47·0 (−0·47) −1·67 No Dystonic CP
16 2 27·0 44·5 28·9 Yes 4 None No 49·0 (+1·01) −0·14 No Dystonic CP
17 2 28·2 39 35·1 Yes 3 None No 47·8 (+0·05) −2·78 Yes Choreo-athetotic CP
18 2 27·2 64 78·8 Yes 2 None No 49·5 (+1·35) 1·54 Yes Unilateral CP, left hemiplegia
19 3 27·4 51 75·9 Yes 3 None No 47·0 (−0·45) −0·24 No Bilateral CP, diplegia
20 2 29·7 61·5 83·5 Yes 1 None No 49·5 (1·15) −1·30 Yes Bilateral CP, diplegia
21 2 29·8 70 30·9 Yes 3 None Yes 44·0 (−1·29) −3·34 No Unclassiﬁable CP, global
hypotonia
22 1 27·8 62 53·6 Yes 2 None No 46·4 (−1·67) −2·57 Yes Unclassiﬁable CP, global
hypotonia
23 2 28·9 71 36·4 No 0 None No 42·0 (−4·14) −3·84 Yes Global developmental delay,
microcephaly
24 3 28·1 71 66·2 No 0 None No 43·0 (−3·36) −4·38 Yes Global developmental delay,
microcephaly
25 2 28·4 77 61·3 No 0 None No 44·5 (−3·08) −1·50 Yes Global developmental delay,
microcephaly
26 2 27·3 73 41·8 No 0 None Yes 46·9 (−0·51) −1·26 Yes AT Global developmental delay
27 2 27·2 74 52·2 No 0 None No 47·5 (−0·07) 0·30 Yes Global developmental delay
28 2 27·3 78 66·3 No 0 None No 47·5 (−0·09) 0·11 Yes Global developmental delay
29 2 27·9 77 65·9 No 0 None No 47·8 (+0·08) −0·10 Yes AT Global developmental delay
30 2 27·6 76 67·8 No 0 None No 48·5 (+0·61) −0·70 Yes Global developmental delay
31 1 28·3 78 58·7 No 0 None No 50·5 (+1·97) 0·13 Yes Global developmental delay
32 2 28·1 76·5 56·2 No 0 None No 48·2 (−0·39) −0·39 Yes Global developmental delay
33 2 28·1 78 61·6 No 0 None Yes 44·4 (−2·36) 0·03 Yes Global developmental delay
34 3 27·0 76 55·9 No 0 None No 45·5 (−1·49) −0·58 Yes Global developmental delay
Comparison cohort
1 0 28·6 67·5 72·0 Yes 2 None No 47·0 (−1·29) −2·11 Yes AT Bilateral CP, mild diplegia
2 0 27·5 58·5 72·4 Yes 1 None No 48·0 (+0·25) −1·23 Yes Dystonic CP
3 0 29·3 78 51·4 No 0 None No 46·8 (−0·75) −0·70 Yes Global developmental delay
CP=Cerebral Palsy; DQ, Developmental quotient; GMFCS, Gross Motor Function Classiﬁcation System; HI = hearing impairment; HINE = Hammersmith Infant Neurological Examina-
tion; OFC, Occipito-frontal circumference; VI = visual impairment; AT = with assistive technology.
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(weight-for-age Z-score b−2, 44·1% in impaired vs. 3·7% unimpaired,
RR12·1(3·7–39·0) and height-for-age Z-score b−2, 5·9% in impaired
vs.18·3% in unimpaired, RR2·9(1·7–5·0)). A third of NE children with
NDI (35·3%) had severe undernutrition (weight-for-age Z-score b
−3) versus none without NDI.
Mean Hb levels were slightly lower in NE survivors, however, the
prevalence of anaemia was similar. Chest infections were more com-
mon amongst children with NE than in the non-NE group (22/116
(19·0%) and 18/230(7·8%) respectively, p = 0·002) and amongst NE
survivors with NDI than those without NDI (10/34(29·4%) and 12/82
(14·6%), p = 0·07).3.1.5. Mortality After NE
Neonatal fatality amongst the encephalopathy and non-NE cohorts
has been reported previously [12]. In the encephalopathy cohort, most
deaths, 91·4% (64/70), occurred before day 4 and 98·6% (69/70) before
day 8 (Fig. 3). Mortality in the NE and non-NE cohorts are shown in
Table 5.
In the NE cohort, six children died in early infancy (two moderate
and four severe NE). Causes of death (parental report) included
pneumonia(n = 2), seizures(n = 2), diarrhoea and vomiting(n = 1)
and unknown(n = 1). A further ﬁve children died between 12 and
27 months. Four had been assessed at 12 months to have severe four-
limb CP following severe NE. Cause of death was attributed to seizures
Fig. 3. Survival estimates for those with and without neonatal encephalopathy during the
neonatal period.
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child had CP with severe motor delay but otherwise normal develop-
ment followingmoderate NE; the cause of death was given as pneumo-
nia. Amongst the non-NE group, seven infants died in the ﬁrst ﬁfteen
months (pneumonia/febrile illness(n = 5), cardiac condition(n = 1),
motorcycle accident(n = 1), unknown(n = 1).
3.1.6. Clinical Predictors of Death and Disability After NE
The risk of an adverse outcome (death or NDI) signiﬁcantly in-
creased with NE severity [16]. Death or NDI occurred in 21·7%(5/23)
with mild, 50·9%(54/106) with moderate and 82·4%(56/68) were
severe NE (p b 0·0001, trend). Similarly, with the Thompson score,
37·5% (30/80) with score 6–10, 68·8%(66/96) with score 11–14, and
90·5%(19/21) with score 15–22 had an adverse outcome (p b 0·0001,
trend). Adverse outcome was more common amongst those with en-
dogenous hypothermia on day 1 (60·9% with hypothermia vs. 48·7%
without, RR1·25(0·88–1·78)). No signiﬁcant outcome differences
were seen between those with and without proven neonatal serious
bacterial infection; 68·6%(11/16) with bacteraemia vs. 57·5%(104/
181) without (p = 0·38). cUS abnormality (in BGT and/or WM) on
day 4/5 was strongly associated with increased risk of adverse outcome
(39/47(83·0%) for abnormal scans versus 6/46(13·0%) for normal
scans), RR6·4(3·0, 13·6)).
The risk of NDI amongst survivors increased signiﬁcantlywithNE se-
verity (Table 6), neonatal clinical seizures, an abnormal cUS on day 4/5
and nasogastric feeding at discharge but not day 1 endogenous hypo-
thermia (Table 6). All children with OFC z-score b−2 at one year had
NDI at 27–30 months.
4. Discussion
We report here on survival, developmental, and nutritional out-
comes of children after NE in a sub-Saharan African setting [2,4]. Our
large NE and comparison cohorts, low loss-to follow-up rates and com-
prehensive neurodevelopmental assessments allow us to give accurateTable 5
Mortality in the neonatal encephalopathy (NE) and comparison, non-NE cohorts.
Follow-up period Encephalopathy
cohorta
Comparison
cohorta
p-value
(chi squared test)
p-value
(log rank test)
Neonatal 70/208 (33.7%) 1/396 (0.3%) b0.001 b0.001
Post-neonatal 11/127 (8.4%) 8/238 (3.4%) 0.03 0.008
Birth to 27months 81/201 (40.3%) 9/239 (3.8%) b0.001 b0.001
a Numerator = number of deaths during follow-up period, denominator = number of
participants for whom vital status known at end of follow-up period.early childhood outcomes after NE in this urban Ugandan population.
A third of survivors were affected by neurodevelopmental impairments.
Bilateral spastic CP, frequently with dystonia was common and strongly
associated with multi-domain impairment. Several clinical parameters
strongly predicted adverse outcome at two including severity of NE,
presence of neonatal seizures, abnormalities on cranial ultrasound, per-
sistent neonatal feeding difﬁculties and a small head circumference at
one year. Most deaths after NE occurred in the neonatal period and
post-neonatal mortality high amongst children identiﬁed to have CP.
In our sub-Saharan African study, 2-year disability-free survival oc-
curred in 41·6% of NE survivors. This is not dissimilar to studies from
high-income country settings; disability-free survival was 46·9%
amongst the control arm of the Toby therapeutic hypothermia trial
(UK) [27] and 39% in Western Australia [3] although differing deﬁni-
tions of NE and differing survival rates affect study comparability. In
our setting, a high proportion of NE survivors had moderate or severe
NDI at 2 years compared to normal term-born children. Severe, bilateral
spastic CP was the most common condition, followed by severe GDD
without CP. Hearing and visual impairment only occurred with NDI,
but may be underestimated since neurophysiological assessments
could not be performed.
Malnutrition was common amongst those with NDI, of whom nearly
half had moderate or severe undernutrition and/or stunting. This likely
reﬂects feeding difﬁculties associated with severe CP as well as increased
use of calories. Assessing nutritional status amongst children with
neurodisability presents challenges [28] but maintaining good nutrition
is crucial to maximising their health, functioning and quality of life [29].
Important differences were also seen in neurodevelopmental out-
come after excluding children with CP and GDD from both cohorts. As
in theWestern Australia study [3], children who had NE but did not de-
velop CP or GDDwere still at increased risk of poorer motoring function
compared to children without NE. Previous studies have shown motor
problems in children without CP after HIE [30]. Published data on later
childhood outcomes after NE in LMICs is lacking. Longer-term follow-
up of our cohort is needed to assess differences in cognitive and behav-
ioural outcomes likely unapparent at this early age.
The highest risk of death after NE was seen in the early neonatal pe-
riod, consistent with other studies from LMICs [25]. This increased risk
continued however through the ﬁrst two years with NE survivors at
three times the risk of post-neonatal death compared to the non-NE co-
hort. InNE survivorsmost deathswere related to severe, four-limb spas-
tic CP with deaths from pneumonia and childhood seizures the most
common. The substantial contribution of term-age neonatal illness to
the aetiology of CP in this urban Ugandan setting has been reported by
us previously [26]. Since studies examining the aetiology of CP com-
monly use a 2-year age cut-off, high early childhood mortality rates
amongst impaired NE survivors may lead to under-estimation of the
contribution of NE to childhood disability in this setting.
We identiﬁed simple clinical predictors of NDI after NE including
clinical severity of NE, presence of neonatal clinical seizures, the need
for continued feeding support and small head circumference at one
year. Identiﬁcation of simple, early clinical predictors of outcome has
the potential to support targeted neurodevelopmental follow-up in
those at highest risk in low resource settings. It was not our intention
to report on the sequential development of children within this paper,
although it would be valid and of interest to do so. We have retained
our focus on two-year outcomes when cerebral palsy can be more reli-
ably diagnosed and assessment below this age may miss impairment.
Short cohort follow-up has been a major limitation of previous studies
in this ﬁeld.
4.1.1. Strengths and Limitations
We achieved high follow-up rates amongst NE survivors and
lower rates amongst the non-NE cohort, with some baseline socio-
demographic differences between those who were and were not
followed which could lead to bias when comparing the NE and
Fig. 4. Grifﬁths Mental Development Scales global developmental quotient (DQ) and six-subscale scores of comparison group, NE survivors without impairment, and those with
impairment. The blue, red and green bars represent comparison cohort without neonatal encephalopathy (non-NE) with no NDI, neonatal encephalopathy (NE) cohort with no NDI,
and NE cohort with NDI, respectively. P-values for comparison between NE cohort with NDI and the other two groups all b0.001.
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tions was taken from parent handheld records, veriﬁed by clinician
report however reporting bias cannot be excluded. Risk of observer
bias was minimised; all children being assessed by examiners blind
to NE status and clinical data. All children were videoed, and those
with suboptimal scoring reviewed to ensure correct diagnosis andTable 6
Clinical predictors of impairment at two years in neonatal encephalopathy survivors.
Clinical predictor NDI
N (%)
RR (95% CI) p-value
Severity of encephalopathy: Sarnat
staging [16]
Mild 2/20 (10·0%) 1 0·04
Moderate 22/74 (29·7%) 3·0 (0·8, 11·6)
Severe 10/22 (45·5%) 4·6 (1·1, 18·3)
Severity of encephalopathy:
Thompson score [13]
6–10 13/63 (20·6%) 1 0·01
11–14 16/46 (34·8%) 6·3 (3·4, 11·8)
15–22 5/7 (71·4%) 13·0 (6·7, 25·3)
Neonatal clinical seizures
No 7/60 (11.7%) 1
Yes 27/56 (48.2%) 4.1 (2.0, 8.7) b0·001
Hypothermia day 1 (axillary
temperature b 36·5C)
No 7/26 (26·9%) 1
Yes 27/88 (30·7%) 1·1 (0·6, 2·3) 0·71
Cranial ultrasound abnormality on
early (day 1) scan
No abnormality 29/90 (32·2%) 1
Abnormality 5/13 (38·5%) 1·2 (0·6, 2·5) 0·66
Cranial ultrasound abnormality on
late (day 4/5) scan
No abnormality 5/45 (11·1%) 1
Abnormality 28/36 (77·8%) 7·0 (3·8, 16·3) b0·001
Nasogastric feeding on discharge
No 15/85 (17·7%) 1
Yes 19/30 (63·3%) 3·6 (2·1, 6·1) b0·001
Occipito-frontal head circumference at one year of agea
Z-score b−2 (b41·8 cm) No 27/109 (24·8%) 1
Yes 7/7 (100·0%) 4·9 (2·9, 5·6) b0·001
Z-score b−3 (b39·5 cm) No 32/114 (28·1%) 1
Yes 2/2 (100·0%) 3·6 (2·7, 4·8) 0·03
RR = Risk Ratio; CI=Conﬁdence Intervals.
a Cut-offs for occipito-frontal head circumferencewas determined as comparison group
mean – 2 comparison group SD and mean – 3 comparison SD.typing of impairment. A comparison cohort of term children without
NE allowed comparison of GMDS and HINE scores, as standardised
Ugandan data for these tests is not available. The lack of a
standardised deﬁnition of NE limits the comparability of data be-
tween countries and resource settings. A large number of statistical
tests were undertaken; however, our results are consistent, both in-
ternally and externally, thus our ﬁndings are unlikely to be due to
multiplicity.
5. Conclusion
Death and disability after NE at two years of age are common in this
low resource sub-Saharan African setting. Severe, four-limb CP is the
most common disability, and this is often associated with global devel-
opmental problems, malnutrition and seizure disorders. The high bur-
den of early mortality amongst children with severe impairment in
this setting means that the contribution of NE to childhood disability
may be under-estimated. This study has identiﬁed simple clinical pa-
rameters that may facilitate targeted follow-up of infants at greatest
risk. Children without overt impairment had an increased risk of delay
in motor functioning. It is important to undertake longer-term follow-
up to determine whether further problem emerge as educational,
motor and social demands increase. Strategies for the prevention of
NE, and early intervention for those affected by neurodisability, are ur-
gently needed in LMICs to maximise functional and nutritional out-
comes and quality of life for affected children and their caregivers.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.eclinm.2018.12.001.
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